The health care products company is scheduled to report second-quarter earnings on April 27. Analysts, on average, expect earnings of $1.03 a share on revenue of $2.89 billion."With several compelling newer products on the market across the medical device portfolio (LigaSure small jaw, Endo GIA with Tri‐Staple technology, Everflex with an SFA indication, Pipeline, and Solitaire), the Newport acquisition should clear headwinds facing Covidien's key medical device business this year," William Blair analysts wrote in a March 23 report. "We anticipate the company will generate mid‐ to high‐single‐digit revenue growth from this unit (on a constant‐currency basis) over the next two years." Forward Annual Dividend Yield: 1.7% Rated "A (Buy)" by TheStreet Ratings: The company's first-quarter gross profit margin was about the same as it was last year. Covidien has average liquidity. Its Quick Ratio is 1.47, which shows the company can technically meet its short-term cash needs. In the first quarter, stockholders' net worth increased 9.95% from the prior year. TheStreet Ratings' price target is $61.92. The stock closed Thursday at $53.93 and has risen 19.82% year to date.
Comcast The media giant is scheduled to report first-quarter earnings on May 1. Analysts, on average, anticipate earnings of 42 cents a share on $14.43 billion in revenue. "Upon review, it appeared as if ARPU growth had been too meager and margins too flat for the core residential business in our prior model, with too-aggressive Business Services margin expansion (however, we do still see a 5-year +30% revenue
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts